ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

SBFM Sunshine Biopharma Inc

0.8314
-0.0061 (-0.73%)
Pre Mercado
Última actualización: 04:44:41
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Sunshine Biopharma Inc SBFM NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.0061 -0.73% 0.8314 04:44:41
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.8375
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
06/3/202415:05EDGAR2Form 8-K - Current report
05/3/202415:37EDGAR2Form PRE 14C - Other preliminary information statements
05/3/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202415:03EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/2/202415:28EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/2/202407:24EDGAR2Form PRE 14C - Other preliminary information statements
16/2/202416:01EDGAR2Form 8-K - Current report
15/2/202410:39EDGAR2Form 8-K - Current report
14/2/202414:53EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202410:18EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
12/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
12/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202408:04EDGAR2Form 8-K - Current report
09/2/202416:17EDGAR2Form S-1/A - General form for registration of securities..
01/2/202415:17EDGAR2Form S-1 - General form for registration of securities under..
30/1/202411:38EDGAR2Form 8-K - Current report
08/1/202407:10EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/12/202315:59EDGAR2Form 8-K - Current report
04/12/202307:30GLOBESunshine Biopharma Moves Principal Office to New York City
13/11/202308:00EDGAR2Form 8-K - Current report
13/11/202307:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202311:18EDGAR2Form 8-K - Current report
20/10/202312:06EDGAR2Form 8-K - Current report
19/10/202311:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
18/10/202312:32EDGAR2Form DEF 14A - Other definitive proxy statements
13/10/202309:44EDGAR2Form 8-K - Current report
05/9/202315:20EDGAR2Form DEF 14A - Other definitive proxy statements
25/8/202314:16EDGAR2Form PRE 14A - Other preliminary proxy statements
11/8/202308:00EDGAR2Form 8-K - Current report
11/8/202307:30GLOBESunshine Biopharma Reports 2023 Second Quarter Results:..
10/8/202316:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
16/5/202308:58GLOBESunshine Biopharma Announces Closing of $5.0 Million Private..
12/5/202307:00GLOBESunshine Biopharma Announces Pricing of $5.0 Million Private..
11/5/202308:00GLOBESunshine Biopharma Reports 2023 First Quarter..

Su Consulta Reciente

Delayed Upgrade Clock